Proteomics in Research Phases

Through our comprehensive proteomics services, we are committed to advancing your drug discovery, preclinical development, and clinical research program in a timely and cost-effective manner. No matter what stage of your research is on, our next-generation proteomics platform provides unparalleled depth, accuracy, and throughput services to support your drug and disease research.

Creative proteomics adapted the DIA MS technology to establish our unique and advanced discovery proteomics platform. We provide integrated insights from the expression proteomics, functional proteomics, and structural proteomics levels to accelerate your research process. Moreover, partnering with the world's leading biopharmaceutical companies and research institutions means we are constantly evolving and advancing our full suite of quantitative proteomics services.

Proteomics Research Boosts New Drug Discovery

Various small-molecule bioactive molecules exert their functions by interacting with protein targets, and an increasing number of drugs are exhibited to target multiple proteins. Thus, revealing the target of a small molecule compound is key to gaining insight into action mechanisms and potential toxicity. Drug target identification not only deepens the understanding of drug action mechanisms but also reveals the potential therapeutic applications and adverse effects. Our discovery proteomics platform can quantify thousands of proteins per sample of almost any biological sample.

Small Molecule Drug Target Deconvolution Solutions

Enable the identification of significantly regulated proteins in disease models for therapeutic exploration.

Proteomics Enables Preclinical Evaluation More Accurate

Comparing the difference in proteomic expression between cells or tissues in health and disease states makes it possible to identify the action mechanism of small molecule drugs and characterize molecular pathways. Analyzing how disease-related proteins aggregate, identifying the interaction partners of native and aggregated pathological proteins, and determining the consequences of protein aggregation will likely elucidate the pathomechanisms. Creative Proteomics can provide a broader and deeper understanding of small molecule drug targets and associated signaling pathways in the preclinical phase with proteomic methods to accelerate your research process.

Drug's Mechanism of Action

Study the mechanisms by which small molecule drugs interact with the proteome .

Proteomics Accelerates Clinical Research

A biomarker is a characteristic biochemical indicator that can be objectively evaluated to determine the biological process of an organism. The examination of a disease-specific biomarker can play a crucial role in diagnosing and preventing the disease. Creative Proteomics can provide proteomic analysis of clinical samples, such as tissue and body fluid samples, to discover and validate new biomarkers.